Crohn’s disease can cause significant morbidity, including nutritional deficiencies, fatigue and the development of strictures, fistulas and abscesses. A wide range of therapies exist for use in clinical practice, which aim to alter the natural course of the disease and improve quality of life for affected patients.
There has been little change in diagnostic and management approaches for polymyalgia rheumatica since the 1950s. With the advent of diagnostic imaging techniques and recent FDA approval of the first biologic agent for relapsing disease in the US, modern medicine may soon become a reality for patients with this condition.
The 2023 international guideline for the assessment and management of polycystic ovary syndrome introduces several key changes. The updates emphasise holistic patient care to address the associated cardiometabolic risks and complications and psychosocial challenges.
Recent evidence supports the benefits of lipid-lowering therapy for older people, suggesting chronological age alone should not be a barrier to its use.
New therapies are emerging to reduce the adverse cardiovascular outcomes and progression of chronic kidney disease in type 2 diabetes. All patients with diabetes should be screened for diabetic kidney disease and, where possible, considered candidates for therapy.
Interstitial lung disease is characterised by a diverse spectrum of disease and is often associated with significant morbidity and mortality. The PBS criteria for antifibrotic therapy now include all progressive phenotypes, emphasising the importance of early disease recognition and referral to a respiratory specialist for further management.
